County
Campbell County Emergency Medical Service
Campbell County Emergency Medical Service (TN) carries 44 drugs across 200 dose entries in its current published protocol, effective 2025-05-27.
Drugs and doses44
Acetaminophen
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Mild to moderate pain | adult | 325–1000 mg | PO | not captured | standing | page 148 |
| Mild to moderate pain | peds | 10–15 mg/kg | PO | not captured | standing | page 148 |
Adenosine
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| SVT | adult | 12 mg | IV | not captured | standing | page 25 |
| SVT | peds | 0.1 mg/kg | IV | not captured | standing | page 25 |
| Wide-complex tachycardia | adult | 12 mg | IV | not captured | standing | page 25 |
| Wide-complex tachycardia | peds | 0.1 mg/kg | IV | not captured | standing | page 25 |
Albuterol
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Asthma / bronchospasm | adult | 2.5 mg | NEB | not captured | standing | page 64 |
| Asthma / bronchospasm | peds | 2.5 mg | NEB | not captured | standing | page 64 |
| CHF / pulmonary edema | adult | 2.5 mg | NEB | not captured | standing | page 49 |
| CHF / pulmonary edema | adult | 2.5 mg | NEB | not captured | standing | page 49 |
| COPD | adult | 2.5 mg | NEB | not captured | standing | page 64 |
| COPD | peds | 2.5 mg | NEB | not captured | standing | page 64 |
| Crush injury | adult | 5 mg | NEB | not captured | standing | page 144 |
| Other | adult | 2.5 mg | NEB | not captured | standing | page 128 |
| Respiratory distress | adult | 2.5 mg | NEB | not captured | standing | page 64 |
| Respiratory distress | peds | 2.5 mg | NEB | not captured | standing | page 64 |
Amiodarone
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Other | adult | 150–300 mg | IV/IO | not captured | standing | page 24 |
| Other | adult | 300 mg | IV | not captured | standing | page 31 |
| Other | peds | 5 mg/kg | IV/IO | not captured | standing | page 24 |
| Other | peds | 5 mg/kg | IV | not captured | standing | page 31 |
| Wide-complex tachycardia | adult | 150 mg | IV/IO | not captured | standing | page 30 |
| Wide-complex tachycardia | peds | 5 mg/kg | IV/IO | not captured | standing | page 30 |
| VF / pulseless VT | adult | 300 mg | IV/IO | not captured | standing | page 28 |
| VF / pulseless VT | peds | 5 mg/kg | IV/IO | not captured | standing | page 28 |
Amyl Nitrite
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Other | adult | 1 ampule | NEB | not captured | standing | page 137 |
Aspirin
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| ACS / chest pain | adult | 324 mg | PO | not captured | standing | page 19 |
Atropine
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Asystole / PEA | adult | 0.5 mg | IV | not captured | standing | page 18 |
| Bradycardia | adult | 0.5 mg | IV | not captured | standing | page 18 |
| Bradycardia | peds | 0.02 mg/kg | IV | not captured | standing | page 18 |
| Nerve agent exposure | peds | 0.05 mg/kg | IV/IO/IM | not captured | standing | page 42 |
Calcium Chloride
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Asystole / PEA | adult | 500 mg | IV | not captured | standing | page 27 |
| Asystole / PEA | peds | 20 mg/kg | IV | not captured | standing | page 27 |
| Crush injury | adult | 1 g | IV | not captured | standing | page 145 |
| Crush injury | peds | 20 mg/kg | IV | not captured | standing | page 145 |
| Hyperkalemia | adult | 500 mg | IV | not captured | standing | page 23 |
| Hyperkalemia | peds | 20 mg/kg | IV | not captured | standing | page 23 |
| Tricyclic overdose | adult | 500 mg | IV | not captured | standing | page 23 |
| Tricyclic overdose | peds | 20 mg/kg | IV | not captured | standing | page 23 |
| VF / pulseless VT | adult | 500 mg | IV | not captured | standing | page 28 |
| VF / pulseless VT | adult | 500 mg | IV | not captured | standing | page 28 |
| VF / pulseless VT | peds | 20 mg/kg | IV | not captured | standing | page 28 |
| VF / pulseless VT | peds | 20 mg/kg | IV | not captured | standing | page 28 |
Diazepam
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Eclampsia / pre-eclampsia | adult | 5 mg | IV | not captured | standing | page 103 |
| Nerve agent exposure | peds | 0.1 mg/kg | IV/IO | not captured | standing | page 42 |
| Other | adult | 2–5 mg | IV/IO/IM | not captured | standing | page 34 |
| Other | peds | 0.1 mg/kg | IV/IO/IM | not captured | standing | page 34 |
| Other | peds | 0.1 mg/kg | IV | not captured | standing | page 43 |
| Seizure | adult | 2–5 mg | IV/IO/IM | not captured | standing | page 65 |
| Seizure | peds | 0.1 mg/kg | IV/IO/IM | not captured | standing | page 65 |
| SVT | adult | 2–5 mg | IV | not captured | standing | page 25 |
| SVT | peds | 0.1 mg/kg | IV | not captured | standing | page 25 |
| Wide-complex tachycardia | adult | 2–5 mg | IV | not captured | standing | page 30 |
| Wide-complex tachycardia | peds | 0.1 mg/kg | IV | not captured | standing | page 30 |
| VF / pulseless VT | adult | 2–5 mg | IV | not captured | standing | page 26 |
| VF / pulseless VT | peds | 0.1 mg/kg | IV | not captured | standing | page 26 |
Diltiazem
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Atrial fibrillation with RVR | adult | 0.25 mg/kg | IV | not captured | standing | page 154 |
| SVT | adult | 0.25 mg/kg | IV | not captured | standing | page 25 |
| Narrow-complex tachycardia | adult | 0.25 mg/kg | IV | not captured | standing | page 154 |
Dimercaprol
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Other | adult | 3 mg/kg | IM | not captured | standing | page 133 |
Diphenhydramine
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Anaphylaxis | adult | 25–50 mg | IV/IM | not captured | standing | page 51 |
| Anaphylaxis | peds | 1 mg/kg | IV/IM | not captured | standing | page 51 |
Dopamine
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Cardiogenic shock | adult | 2–20 mcg/kg | IV | not captured | standing | page 74 |
| Cardiogenic shock | peds | 2–20 mcg/kg | IV | not captured | standing | page 74 |
| Other | adult | 2–20 mcg/kg | IV | not captured | standing | page 84 |
| Other | peds | 2–20 mcg/kg | IV | not captured | standing | page 84 |
| Sepsis | adult | 2–20 mcg/kg | IV | not captured | standing | page 82 |
| Sepsis | peds | 2–20 mcg/kg | IV | not captured | standing | page 82 |
| Trauma / hemorrhage | adult | 2–20 mcg/kg | IV | not captured | standing | page 77 |
| Trauma / hemorrhage | adult | 2–20 mcg/kg | IV | not captured | standing | page 85 |
| Trauma / hemorrhage | adult | 2–20 mcg/kg | IV | not captured | standing | page 88 |
| Trauma / hemorrhage | peds | 2–20 mcg/kg | IV | not captured | standing | page 77 |
| Trauma / hemorrhage | peds | 2–20 mcg/kg | IV | not captured | standing | page 85 |
| Trauma / hemorrhage | peds | 2–20 mcg/kg | IV | not captured | standing | page 88 |
Droperidol
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Agitation | adult | 5 mg | IM | not captured | standing | page 125 |
| Agitation | adult | 5 mg | IV | not captured | standing | page 125 |
| Nausea / vomiting | adult | 0.625–2.5 mg | IM | not captured | standing | page 152 |
| Nausea / vomiting | adult | 0.625–2.5 mg | IV | not captured | standing | page 152 |
| Nausea / vomiting | peds | 0.015–0.1 mg/kg | IM | not captured | standing | page 152 |
| Nausea / vomiting | peds | 0.015–0.1 mg/kg | IV | not captured | standing | page 152 |
Epinephrine
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Anaphylaxis | adult | 0.3–0.5 mg | IM | not captured | standing | page 51 |
| Anaphylaxis | peds | 0.01 mg/kg | IM | not captured | standing | page 51 |
| Bradycardia | adult | 2–10 mcg | IV/IO | not captured | standing | page 18 |
| Cardiac arrest | adult | 0.5–1 mg | IV/IO | not captured | standing | page 15 |
| Cardiac arrest | peds | 0.01 mg/kg | IV/IO | not captured | standing | page 15 |
| Croup | peds | 3 mg | NEB | not captured | standing | page 55 |
| Hypotension / shock | adult | 5–10 mcg | IV | not captured | standing | page 18 |
| Respiratory distress | adult | 0.3–0.5 mg | IM | not captured | standing | page 64 |
| Respiratory distress | peds | 0.01 mg/kg | IM | not captured | standing | page 64 |
Etomidate
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| RSI induction | adult | 0.3 mg/kg | IV | not captured | standing | page 168 |
| RSI induction | peds | 0.3 mg/kg | IV | not captured | standing | page 168 |
Fentanyl
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Mild to moderate pain | adult | 1–2 mcg/kg | IV | not captured | standing | page 223 |
| Mild to moderate pain | adult | 1–2 mcg/kg | IM | not captured | standing | page 223 |
| Mild to moderate pain | adult | 1–2 mcg/kg | IN | not captured | standing | page 179 |
| Mild to moderate pain | peds | 0.5–2 mcg/kg | IV | not captured | standing | page 223 |
| Mild to moderate pain | peds | 0.5–2 mcg/kg | IM | not captured | standing | page 223 |
| Mild to moderate pain | peds | 0.5–2 mcg/kg | IN | not captured | standing | page 179 |
| Post-intubation sedation | adult | 1–2 mcg/kg | IV | not captured | standing | page 225 |
| RSI induction | adult | 2 mcg/kg | IV | not captured | standing | page 168 |
| RSI induction | peds | 2 mcg/kg | IV | not captured | standing | page 168 |
Glucagon
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Beta-blocker / calcium-channel-blocker overdose | adult | 1–2 mg | IV/IM | not captured | standing | page 18 |
| Beta-blocker / calcium-channel-blocker overdose | peds | 0.5–1 mg | IV/IM | not captured | standing | page 18 |
| Hypoglycemia | adult | 1–2 mg | IV/IM | not captured | standing | page 65 |
| Hypoglycemia | peds | 0.5–1 mg | IV/IM | not captured | standing | page 65 |
Haloperidol
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Agitation | adult | 5 mg | IM | not captured | standing | page 125 |
| Agitation | adult | 5–10 mg | IV | not captured | standing | page 125 |
Hydroxocobalamin
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Cyanide poisoning | adult | 5 g | IV | not captured | standing | page 131 |
| Cyanide poisoning | adult | 5 g | IV | not captured | standing | page 131 |
Ibuprofen
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Mild to moderate pain | adult | 400–800 mg | PO | not captured | standing | page 147 |
| Mild to moderate pain | peds | 5–10 mg/kg | PO | not captured | standing | page 147 |
Insulin
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Crush injury | adult | 10 unit | IV | not captured | standing | page 144 |
| Crush injury | peds | 0.2 unit/kg | IV | not captured | standing | page 144 |
Ipratropium
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| CHF / pulmonary edema | adult | 0.05 mg | NEB | not captured | standing | page 49 |
| CHF / pulmonary edema | adult | 0.05 mg | NEB | not captured | standing | page 49 |
Ketamine
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Agitation | adult | 4 mg/kg | IV/IM | not captured | standing | page 119 |
| Hyperactive delirium | adult | 4 mg/kg | IV/IM | not captured | standing | page 122 |
| Mild to moderate pain | peds | 0.25–0.5 mg/kg | IV/IM/IN | not captured | standing | page 221 |
| Post-intubation sedation | adult | 1–2 mg/kg | IV | not captured | standing | page 225 |
| Post-intubation sedation | peds | 1–2 mg/kg | IV | not captured | standing | page 225 |
| Seizure | peds | 1 mg/kg | IV/IM | not captured | standing | page 65 |
Ketorolac
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Severe pain | adult | 10–30 mg | IV | not captured | standing | page 148 |
| Severe pain | adult | 30–60 mg | IM | not captured | standing | page 148 |
Lidocaine
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Mild to moderate pain | adult | 20–50 mg | IO | not captured | standing | page 181 |
| Mild to moderate pain | peds | 0.5 mg/kg | IO | not captured | standing | page 181 |
| VF / pulseless VT | adult | 1–1.5 mg/kg | IV/IO | not captured | standing | page 28 |
| VF / pulseless VT | adult | 1–1.5 mg/kg | IV/IO | not captured | standing | page 28 |
| VF / pulseless VT | peds | 1 mg/kg | IV/IO | not captured | standing | page 28 |
| VF / pulseless VT | peds | 1 mg/kg | IV/IO | not captured | standing | page 28 |
Lorazepam
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Nerve agent exposure | adult | 1–2 mg | IV | not captured | standing | page 42 |
| Nerve agent exposure | peds | 0.1 mg/kg | IV | not captured | standing | page 42 |
| Other | adult | 1–2 mg | IV | not captured | standing | page 34 |
| Other | peds | 0.1 mg/kg | IV | not captured | standing | page 34 |
| Seizure | adult | 1–2 mg | IV | not captured | standing | page 65 |
| Seizure | peds | 0.1 mg/kg | IV | not captured | standing | page 65 |
Magnesium Sulfate
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Asthma / bronchospasm | adult | 1–2 g | IV | not captured | standing | page 64 |
| Asystole / PEA | adult | 1–2 g | IV | not captured | standing | page 27 |
| Eclampsia / pre-eclampsia | adult | 6 g | IV | not captured | standing | page 103 |
| Eclampsia / pre-eclampsia | adult | 6 g | IV | not captured | standing | page 103 |
| VF / pulseless VT | adult | 1–2 g | IV | not captured | standing | page 26 |
| VF / pulseless VT | adult | 1–2 g | IV | not captured | standing | page 27 |
| VF / pulseless VT | adult | 1–2 g | IV | not captured | standing | page 27 |
| VF / pulseless VT | peds | 50 mg/kg | IV | not captured | standing | page 26 |
Methylene Blue
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Other | adult | 1–2 mg/kg | IV | not captured | standing | page 141 |
Methylprednisolone
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Anaphylaxis | adult | 62.5 mg | IV | not captured | standing | page 51 |
| Respiratory distress | adult | 62.5 mg | IV | not captured | standing | page 64 |
Midazolam
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Agitation | adult | 2–5 mg | IV/IM | not captured | standing | page 119 |
| Eclampsia / pre-eclampsia | adult | 2–5 mg | IV/IM | not captured | standing | page 103 |
| Nerve agent exposure | adult | 2–5 mg | IV/IO/IM/IN | not captured | standing | page 42 |
| Nerve agent exposure | peds | 0.1 mg/kg | IV/IO/IM/IN | not captured | standing | page 42 |
| Other | adult | 2–5 mg | IV/IO/IM/IN | not captured | standing | page 34 |
| Other | peds | 0.1 mg/kg | IV/IO/IM/IN | not captured | standing | page 34 |
| Other | peds | 0.1 mg/kg | IV | not captured | standing | page 43 |
| Seizure | adult | 2–5 mg | IV/IO/IM/IN | not captured | standing | page 65 |
| Seizure | peds | 0.1 mg/kg | IV/IO/IM/IN | not captured | standing | page 65 |
| SVT | adult | 2–5 mg | IV | not captured | standing | page 25 |
| SVT | peds | 0.1 mg/kg | IV | not captured | standing | page 25 |
| Wide-complex tachycardia | adult | 2–5 mg | IV | not captured | standing | page 30 |
| Wide-complex tachycardia | peds | 0.1 mg/kg | IV | not captured | standing | page 30 |
| VF / pulseless VT | adult | 2–5 mg | IV | not captured | standing | page 26 |
| VF / pulseless VT | peds | 0.1 mg/kg | IV | not captured | standing | page 26 |
Morphine
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Other | adult | 2–4 mg | IV | not captured | standing | page 60 |
| Mild to moderate pain | adult | 2–10 mg | IV | not captured | standing | page 223 |
| Mild to moderate pain | peds | 0.05–0.1 mg/kg | IV | not captured | standing | page 223 |
| RSI paralysis | adult | 1–10 mg | IV | not captured | standing | page 190 |
| RSI paralysis | peds | 1–10 mg | IV | not captured | standing | page 190 |
Naloxone
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Bradycardia | adult | 0.4–2 mg | IV/IN | not captured | standing | page 17 |
| Opioid overdose | adult | 0.4–2 mg | IV/IO/IM/IN | not captured | standing | page 23 |
| Opioid overdose | peds | 0.1 mg/kg | IV/IO/IM/IN | not captured | standing | page 23 |
Nerve Agent Antidote Kit
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Organophosphate poisoning | adult | 1 kit | IM | not captured | standing | page 143 |
| Organophosphate poisoning | adult | 3 kits | IM | not captured | standing | page 143 |
Nitroglycerin
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| ACS / chest pain | adult | 0.4 mg | SL | not captured | standing | page 19 |
| CHF / pulmonary edema | adult | 0.4 mg | SL | not captured | standing | page 49 |
| Other | adult | 0.4 mg | SL | not captured | standing | page 60 |
Ondansetron
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Nausea / vomiting | adult | 2–4 mg | IV | not captured | standing | page 47 |
| Nausea / vomiting | adult | 8 mg | PO | not captured | standing | page 47 |
| Nausea / vomiting | peds | 0.15 mg/kg | IV | not captured | standing | page 47 |
| Nausea / vomiting | peds | 4 mg | PO | not captured | standing | page 47 |
| Other | adult | 2–4 mg | IV | not captured | standing | page 162 |
| Other | peds | 0.15 mg/kg | IV | not captured | standing | page 162 |
Oral Glucose
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Hypoglycemia | adult | 1 tube | PO | not captured | standing | page 10 |
| Hypoglycemia | peds | 1 tube | PO | not captured | standing | page 10 |
Pralidoxime
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Organophosphate poisoning | adult | 20–50 mg/kg | IV | not captured | standing | page 143 |
| Organophosphate poisoning | adult | 600 mg | IM | not captured | standing | page 143 |
| Organophosphate poisoning | peds | 15 mg/kg | IM | not captured | standing | page 143 |
| Organophosphate poisoning | peds | 20–50 mg/kg | IV | not captured | standing | page 143 |
Promethazine
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Nausea / vomiting | adult | 6.25–25 mg | IV | not captured | standing | page 47 |
Sodium Bicarbonate
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Crush injury | adult | 50 mEq | IV | not captured | standing | page 144 |
| Crush injury | peds | 1 mEq/kg | IV | not captured | standing | page 144 |
| Hyperkalemia | adult | 1 mEq/kg | IV/IO | not captured | standing | page 23 |
| Hyperkalemia | peds | 1 mEq/kg | IV/IO | not captured | standing | page 23 |
| Other | adult | 1–2 mEq/kg | IV | not captured | standing | page 23 |
| Other | adult | 3 mL | NEB | not captured | standing | page 129 |
| Tricyclic overdose | adult | 1 mEq/kg | IV/IO | not captured | standing | page 23 |
| Tricyclic overdose | peds | 1 mEq/kg | IV/IO | not captured | standing | page 23 |
Sodium Nitrite
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Other | adult | 300 mg | IV | not captured | standing | page 137 |
Tetracaine
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Other | adult | 2 drop | not captured | not captured | standing | page 127 |
| Other | adult | 2 drop | not captured | not captured | standing | page 129 |
| Other | adult | 2 drop | not captured | not captured | standing | page 139 |
Tranexamic Acid
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| Trauma / hemorrhage | adult | 2 g | IV | not captured | standing | page 72 |
Vecuronium
| Indication | Population | Dose | Route | Repeat | Standing | Source |
|---|---|---|---|---|---|---|
| RSI paralysis | adult | 0.1 mg/kg | IV | not captured | standing | page 190 |
| RSI paralysis | peds | 0.1 mg/kg | IV | not captured | standing | page 190 |